


INMUNOTHERAPY: RECOGNISING AND TREATING ADVERSE EFFECTS

I. Ruiz Santos, E. Mateos Egido, A. Domínguez Fariña, G. Avanzini Martínez, F. Madriñán González, M. Lombardero Pin
Complejo Hospitalario Universitario Insular-Materno Infantil, Pharmacy, Las Palmas de Gran Canaria, Spain

Background and objectives


- Immunotherapy have changed the landscape of cancer treatment for the last years. Among them, immune checkpoint inhibitors are increasingly used for certain cancers; however, this has resulted in increased reports of immune-related adverse events (irAEs).
- The objective was to identify the irAEs, their gravity, management and appearance time, according to treatment and pathology.

Material and methods



Results

- 612 patients
- 52 irAE
- 61 years old (39-88)
- 67 ± 10 kg
- 227 Days until appearance



Conclusion and relevance

Immunotherapy drugs can occasionally develop some adverse effects. In our study the most common was nephrotoxicity due to pembrolizumab. Despite that, most patients continued treatment once the adverse event was solved. As reported in some guides, the majority of irAEs were solved using methylprednisolone. More studies are needed based on obtaining more specific conclusions.